A randomized, double-blind, placebo-controlled safety study of high-dose dextromethorphan in methadone-maintained male inpatients

Drug and Alcohol Dependence

Volumn 67, Issue 2, 2002, Pages 177-183

  Cornish, James W ^a,f   Herman, Barbara H ^b   Ehrman, Ronald N ^a   Robbins, Steven J ^a,c   Childress, Anna Rose ^a   Bead, Valerani ^a   Esmonde, Catherine A ^a   Martz, Karen ^d   Poole, Sabrina ^a   Caruso, Frank S ^e   O'Brien, Charles P ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c ARCADIA UNIVERSITY   (United States)

^d Ridgeview Statistics   (United States)

^e ENDO PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Addiction; Dextromethorphan; Heroin dependence; Methadone; NMDA; Pharmacotherapy

Indexed keywords

DEXTROMETHORPHAN; METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY TEMPERATURE; BREATHING RATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; EUPHORIA; HEADACHE; HEART RATE; HUMAN; HYPERACTIVITY; INSOMNIA; MAINTENANCE THERAPY; MALE; NAUSEA; NERVOUSNESS; OPIATE ADDICTION; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOMNOLENCE; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

ADULT; ANALYSIS OF VARIANCE; DEXTROMETHORPHAN; DOUBLE-BLIND METHOD; HUMANS; INPATIENTS; MALE; METHADONE; MIDDLE AGED; OPIOID-RELATED DISORDERS;

EID: 18444396274     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(02)00025-X     Document Type: Article

References (23)

1. Dextromethorphan: An overview of safety issues
2. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists
3. Opiate withdrawal with dextromethorphan
4. Role of conditioning factors in the development of drug dependence
5. The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice
6. Dextromethorphan attenuates and reverses analgesic tolerance to morphine
7. N-Methyl-D-Aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development
8. The effect of NMDA receptor antagonists and nitric oxide synthase inhibition on opioid tolerance and withdrawal: Medication development issues for opiate addiction
9. Actions and addiction liabilities of dromoran derivatives in man
10. Morphine (M) with dextromethorphan (D) abuse liability
11. Abuse potential of morphine/dextromethorphan combinations
12. Inhibition by MK-801 of morphine-induced conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice
13. The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with chlorpromazine
14. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats
15. SAFTEE: A technique for the systematic assessment of side effects in clinical trials
16. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man
17. An improved diagnostic evaluation instrument for substance abuse patients: The Addiction Severity Index
18. Conditioning factors in drug abuse: Can they explain compulsion?
19. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists
20. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal
21. Low affinity NMDA receptor channel blockers inhibit initiation of intravenous morphine self-administration in naïve mice
22. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization